Concept Buys CRO Aquila BioMedical

(c) Lichtmeister/Shutterstock
(c) Lichtmeister/Shutterstock

UK-based Concept Life Sciences, an integrated drug discovery, development and analytical services company, has acquired Scottish contract research organization (CRO) Aquila BioMedical for an undisclosed sum.

Aquila, which was spun out of The University of Edinburgh in 2011, has expertise in developing therapeutics for oncology, biomarker discovery and target expression, with services covering a wide range of in vitro and in vivo proof-of-concept studies.

Concept described the acquisition as “a pivotal addition” to its own offering for drug discovery and development. “The company’s offering in translational biology adds significant value to our current discovery services, and broadens the wider group’s therapy offering,” said Concept’s executive chairman, Michael Fort.

Co-founder of Aquila BioMedical, Stephen Anderton, added that Concept’s size, business development network and complementary scientific capacity would significantly accelerate the CRO’s growth.

In September, Concept announced it had expanded into new laboratory space at Alderley Park in Cheshire, UK, increasing its scientific capacity by more than 30% and adding 75 full-time employees. Fort said the “significant” investment would enable Concept to put in place the expertise to support its projected growth in 2018 and beyond.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.